No fine or pentalty imposed on the Company during the quarter.

Ves

Yes

# General information about company

Scrip code 531146
NSE Symbol MEDICAMEQ
MSEI Symbol NOTLISTED
ISIN INE646B01010

Name of the entity

MEDICAMEN BIOTECH LIMITED

Date of start of financial year 01-04-2024
Date of end of financial year 31-03-2025
Reporting Quarter Type Yearly
Date of Quarter Ending 31-03-2025
Type of company Suppose Sequity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Company Yes

Corporate Governance is applicable to the entity?

Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance

Redressal Report is Applicable to the entity?

Yes

Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?

Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?

Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?

Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans /

Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?

Risk management committee Not Applicable

Market Capitalisation as per immediate previous Financial Year Top 2000 listed entities Is SCORE ID Available ? Yes

SCORE Registration ID MOO162
Reason For No SCORE ID

Type of Submission Original

Remarks (website dissemination)

Remarks for Exchange (not for Website Dissemination)

#### Annexure I

#### Annexure I to be submitted by listed entity on quarterly basis

#### I. Composition of Board of Directors

Whether the listed entity has a Regular Chairperson

Disclosure of notes on composition of board of directors explanatory

whether the listed entity has a Regular Chairperson								
		erson is related to MD	or CEO				No	
	Sr Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
	1 Mr	Arun Kumar	AADPK4061G	07031730	Non-Executive - Independent Director	Not Applicable		06-07-1940
	2 Mr	Ashwani Kumar Sharma	AAYPSoo88C	00325634	Non-Executive - Non Independent Director	Not Applicable		14-07-1959
	3 Mr	Harish Pande	AAFPP1715J	01575625	Non-Executive - Independent Director	Not Applicable		22-09-1954
	4 Mr	Rahul Bishnoi	AFEPB2287D	00317960	Non-Executive - Non Independent Director	Chairperson		13-08-1964
	5 Mr	Sanjay Bansal	AELPB1342K	00121667	Non-Executive - Non Independent Director	Not Applicable		12-02-1964
	6 Mr	Suresh Kumar Singh	AITPS9927M	00318015	Non-Executive - Non Independent Director	Not Applicable		01-03-1945
	7 Mrs	Sumita Dwivedi	AXHPD2210K	08218640	Director	Not Applicable		01-07-1970
	8 Mrs	Sangeeta Bishnoi	AHDPB2095A	08288998	Non-Executive - Independent Director	Not Applicable		08-12-1970
	9 Mr	Vimal Kumar Shrawat	AAKPS7192R	08274190	Non-Executive - Non Independent Director	Not Applicable		05-01-1962
	10 Mr	Ravi Kumar Bansal	AAJPB0149G	08462513	Non-Executive - Independent Director	Not Applicable		08-09-1963

#### I. Composition of Board of Directors

# Disqualification of Directors under section 164 of the Companies Act, 2013

Sr Whether the director is disqualified? Start Date of disqualification End Date of disqualification Details of disqualification Current status

No

Active

2 No 3 No 4 No 5 No 6 No 7 No 8 No 9 No	Active
10 No	Active

# I. Composition of Board of Directors

Sı	passed? [Refer Reg.	resolution	Initial Date of appointment	Date of Re- Date of appointment cessation	of director (in	in listed entities including this listed entity (Refer Regulation 17A of Listing	entities including this listed	including this	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	not	Notes for not providing DIN
	Yes	25-09-2019	27-02-2016	27-09-2023	60	2	2	4	0			
2	NA		31-12-2015			2	0	0	0			
3	NA		31-12-2015	25-09-2020	60	3	3	4	4			
4	NA		31-12-2015			2	0	0	0			
5	NA		27-02-2016			2	0	2	0			
6	Yes	25-09-2020	31-12-2015			2	0	0	0			
7	No		13-11-2018	27-09-2023	60	2	2	2	0			
8	NA		11-02-2019	27-09-2023	60	2	2	0	0			
9	NA		11-02-2019			2	0	О	O			
10	) NA		30-05-2019	27-09-2023	60	2	2	О	O			
Λ.	udit Commi	ttaa Dataila										

## **Audit Committee Details**

Whether the Audit Committee has a Regular Chairperson	Yes

Sr DIN Number	r Name of Committee members	s Category 1 of directors	Category 2 of directors	Date of Appointment Date of Cessation Remarks
1 01575625	Harish Pande	Non-Executive - Independent Director	Chairperson	31-12-2015
2 07031730	Arun Kumar	Non-Executive - Independent Director	Member	27-02-2016
3 08218640	Sumita Dwivedi	Non-Executive - Independent Director	Member	13-11-2018

#### Nomination and remuneration committee

Whether the No	omination and remuneration co	ommittee has a Re	egular Chairperson		Yes
Sr DIN Number	r Name of Committee members	s Category 1 of dir	rectors	Category 2 of directors	s Date of Appointment Date of Cessation Remarks
1 01575605	Harich Danda	Non Evocutivo	Indopondent Director	Chairpercon	01 10 0015

1	01575625	Harish Pande	Non-Executive - Independent Director Chairperson	31-12-2015
2	07031730	Arun Kumar	Non-Executive - Independent Director Member	27-02-2016
3	08218640	Sumita Dwivedi	Non-Executive - Independent Director Member	13-11-2018

#### **Stakeholders Relationship Committee**

Whether the Stakeholders Relationship Committee has a Regular Chairperson	Yes
Sr DIN Number Name of Committee members Category 1 of directors	Category 2 of directors Date of Appointment Date of Cessation Remarks

1 01575625	Harish Pande	Non-Executive - Independe	ent Director Chairperson	31-12-2015
2 07031730	Arun Kumar	Non-Executive - Independe	ent Director Member	27-02-2016
3 08218640	Sumita Dwivedi	Non-Executive - Independe	ent Director Member	13-11-2018

#### **Risk Management Committee**

Whether the Risk Management Committee has a Regular Chairperson	Voc
whether the Kisk Management Committee has a Regular Chairberson	res

Sr DIN Number Name of Committee members Category 1 of directors	Category 2 of directors Date of Appointment Date of Cessation Remarks
---	---

1	01575625	Harish Pande	Non-Executive - Independent Director Chairperson	31-12-2015
2	07031730	Arun Kumar	Non-Executive - Independent Director Member	27-02-2016
3	08218640	Sumita Dwivedi	Non-Executive - Independent Director Member	13-11-2018

#### **Corporate Social Responsibility Committee**

Sr <sup>DIN</sup> Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1 01575625	Harish Pande	Non-Executive - Independent Director	Chairperson	02-08-2017		

200121667Sanjay BansalNon-Executive - Non Independent<br/>DirectorMember02-08-2017300318015Suresh Kumar SinghNon-Executive - Non Independent<br/>DirectorMember02-08-2017

#### **Other Committee**

Sr DIN Number Name of Committee members Name of other committee Category 1 of directors Category 2 of directors Remarks

#### Annexure 1

#### Annexure 1

#### III. Meeting of Board of Directors

Disclosure of notes on meeting of board of directors explanatory

	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number o Directors as on date of the meeting	f Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*
1	14-11-2024		number of days)	Date	Yes	10	8	3
2		11-02-2025	88		Yes	10	9	5
3		26-02-2025	14		Yes	10	6	2

#### Annexure 1

#### IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory

S	r Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	requirement	Total Number of Directors in the Committee as on date of the meeting	Present (All	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	14-11-2024				Yes	3	2	2	0
2	Audit Committee	11-02-2025	88			Yes	3	3	3	0
3	Nomination and remuneration committee	14-11-2024				Yes	3	2	2	o
4	Nomination and remuneration committee	11-02-2025	88			Yes	3	3	3	o
5	Corporate Social Responsibility Committee	14-11-2024				Yes	3	2	2	1
6	Corporate Social Responsibility Committee	11-02-2025	88			Yes	3	3	3	1

## Annexure 1

#### IV. Meeting of Committees

S	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Stakeholders Relationship Committee	29-05-2024				Yes	3	2	2	0
8	Risk Management Committee	11-02-2025	257			Yes	3	3	3	0

#### Annexure 1

#### V. Affirmations

Sr Subject					
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes			
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes			
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes			
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes			
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	NA			
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes			

## Annexure 1

Sr Subject Compliance status
1 Name of signatory Parul Choudhary

2 Designation Company Secretary and Compliance Officer

# Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)

#### I. Disclosure on website in terms of LODR Regulation

 $\mathbf{Sr}$ 

Sr Item	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.	Web address
As per regulation 46(2) of the LODR:			
1.1 Details of business	Yes		www.medicamen.com
1.2 Memorandum of Association and Articles of Association	Yes		www.medicamen.com
1.3 Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		www.medicamen.com
2 Terms and conditions of appointment of independent directors	Yes		www.medicamen.com
3 Composition of various committees of board of directors	Yes		www.medicamen.com
4 Code of conduct of board of directors and senior management personnel	Yes		www.medicamen.com
5 Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		www.medicamen.com
6 Criteria of making payments to non-executive directors	Yes		www.medicamen.com
7 Policy on dealing with related party transactions	Yes		www.medicamen.com
8 Policy for determining 'material' subsidiaries	NA		
9 Details of familiarization programmes imparted to independent directors	Yes		www.medicamen.com
10 Email address for grievance redressal and other relevant details	Yes		www.medicamen.com
$^{11}$ Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		www.medicamen.com
12 Financial results	Yes		www.medicamen.com
13 Shareholding pattern	Yes		www.medicamen.com
Details of agreements entered into with the media companies and/or their associates	NA		

# Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)

#### I. Disclosure on website in terms of LODR Regulation

Sr

As per regulation 46(2) of the LODR:

(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.

Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means

NA

NA

Advertisements as per regulation 47 (1)

Credit rating or revision in credit rating obtained

Yes www.medicamen.com

Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year

Yes www.medicamen.com

20 Secretarial Compliance Report	Yes www.medicamen.com
21 Materiality Policy as per Regulation 30 (4)	Yes www.medicamen.com
Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes www.medicamen.com
23 Disclosures under regulation 30(8)	Yes www.medicamen.com
24 Statements of deviation(s) or variations(s) as specified in regulation 32	Yes www.medicamen.com
25 Dividend Distribution policy as per Regulation 43A(1)	Yes www.medicamen.com
26.1 Annual return as provided under section 92 of the Companies Act, 2013	Yes www.medicamen.com
26.2 Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	Yes www.medicamen.com
27 Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes www.medicamen.com
28 Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes www.medicamen.com

# **Annexure II**

#### II. Annual Affirmations

Sr Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.
Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2 Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3 Meeting of Board of directors	17(2)	Yes	
4 Quorum of Board meeting	17(2A)	Yes	
5 Review of Compliance Reports	17(3)	Yes	
6 Plans for orderly succession for appointments	17(4)	Yes	
7 Code of Conduct	17(5)	Yes	
8 Fees/compensation	17(6)	Yes	
9 Minimum Information	17(7)	Yes	
10 Compliance Certificate	17(8)	Yes	

# **Annexure II**

#### II. Annual Affirmations

Regulation Number	Compliance status (Yes/ No/NA)	If status is "No" details of non-compliance may be given here.
17(9)	Yes	
17(10)	Yes	
17(11)	Yes	
17A	Yes	
18(1)	Yes	
18(2)	Yes	
18(3)	Yes	
19(1) & (2)	Yes	
19(2A)	Yes	
19(3A)	Yes	
	Number 17(9) 17(10) 17(11) 17A 18(1) 18(2) 18(3) 19(1) & (2) 19(2A)	Number       No/NA)         17(9)       Yes         17(10)       Yes         17(11)       Yes         18(1)       Yes         18(2)       Yes         18(3)       Yes         19(1) & (2)       Yes         19(2A)       Yes

# **Annexure II**

#### II. Annual Affirmations

Sr Particulars	Regulation Number	Compliance status (Yes/ No/NA)	If status is "No" details of non-compliance may be given here.
21 Role of Nomination and Remuneration Committee	19(4)	Yes	
22 Composition of Stakeholder Relationship Committee	e 20(1), 20(2) & 20(2A)	) Yes	
23 Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24 Role of Stakeholders Relationship Committee	20(4)	Yes	
Composition and role of risk management committee	21(1),(2),(3),(4)	Yes	
26 Meeting of Risk Management Committee	21(3A)	Yes	
27 Quorum of Risk Management Committee meeting	21(3B)	Yes	
$_{\mbox{\footnotesize 28}}$ Gap between the meetings of the Risk Management Committee	21(3C)	Yes	
29 Vigil Mechanism	22	Yes	
30 Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

#### **Annexure II**

#### II. Annual Affirmations

Sr Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.
$^{\rm 31}$ Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32 Approval for material related party transactions	23(4)	Yes	
33 Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34 Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	
36 Alternate Director to Independent Director	25(1)	NA	
37 Maximum Tenure	25(2)	Yes	
38 Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39 Meeting of independent directors	25(3) & (4)	Yes	
40 Familiarization of independent directors	25(7)	Yes	

#### Annexure II

#### II. Annual Affirmations

Sr Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.
41 Declaration from Independent Director	25(8) & (9)	Yes	
42 Directors and Officers insurance	25(10)	NA	
Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA	
44 Memberships in Committees	26(1)	Yes	
45 Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46 Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	Yes	
48 Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
Any other information to be provided - Add Notes			

# **Annexure II**

- 1 Name of signatory Parul Choudhary
- 2 Designation Company Secretary and Compliance Officer

# **Annexure II**

#### III. Affirmations

Sr Particulars

Compliance status (Yes/No/NA)

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied

Any other information to be provided

NA

#### Annexure II

- 1 Name of signatory Parul Choudhary
- 2 Designation Company Secretary and Compliance Officer

# Additional Half yearly Disclosure DISCLOSURE OF LOANS / GUARANTEES / COMFORT LETTERS / SECURITIES ETC. (applicable only for half-yearly filings)

Any Other Information for Disclosure of Loans / Guarantees / Comfort Letters / Securities Etc.

Textual Information(1)

I. Disclosure of Loans/guarantees/comfort letters/securities~etc.~Refer~note~below

(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to

Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	0	0
Promoter Group or any other entity controlled by them	0	0
Directors (including relatives) or any other entity controlled by them	0	0

Aggregate value of

KMPs or any other entity controlled by them

# (B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By

Entity	Type (guarantee, comfort letter etc.)		end of six months(taking into account any invocation)
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	O
Directors (including relatives) or any other entity controlled by them	0	0	O
KMPs or any other entity controlled by them	0	0	0

# (C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by

Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	0	0	O
Promoter Group or any other entity controlled by them	0	0	O
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(D) Additional Information			Textual Information(2)
II. Affirmations			
Affirmations	Compli	ance Status	Company Remarks
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial Yes personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.			
Name	Chandan Kumar		
Designation	CFO		

New Delhi

29-04-2025

# **Details of Cyber security incidence**

Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data No or documents during the quarter

Number of cyber security incidence or breaches or loss of data event occurred during the quarter

Brief details of the Date of the event event

# **Signatory Details**

Place

Date

Parul Choudhary Name of signatory

Designation of person Company Secretary and Compliance Officer

Place New Delhi Date 29-04-2025

#### **Investor Grievance Details**

No. of investor complaints pending at the beginning of Quarter No. of investor complaints received during the Quarter 1 No. of investor complaints disposed off during the Quarter No. of investor complaints those remaining unresolved at the end of the Quarter o

Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies- The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below:

Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies

Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	s Aggregate holding (% shares or voting rights) as at the end of the quarter
1	Opal Pharmaceuticals Pty Ltd	16-09-2019	100	0	100
2	Medicamen Life Sciences Private Limited	1 12-08-2022	60	0	60

# Disclosure of Updates to Ongoing Tax Litigations or Disputes The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes

Sr. No. Name of the opposing party Date of initiation of the litigation / dispute as per last dispute Appeal file and reject in GST appeal Jaipur Appeal file and reject in GST appeal Jaipur Pending for Appeal in GST Tribunal Jaipur O3-12-2021 Appeal file and reject in GST appeal Jaipur Pending for Appeal in GST Tribunal Appeal file and reject in GST appeal Jaipur Pending for Appeal in GST Tribunal